15.1 Hormone Signaling & Hypothalamic-Pituitary Axes

15.1 Hormone Signaling & Hypothalamic-Pituitary Axes

Quick Answer: Peptide hormones → membrane GPCR/RTK + second messengers; steroids/thyroid → nuclear receptors. Hypothalamus drives anterior pituitary with releasing/inhibiting hormones; posterior lobe releases ADH and oxytocin. Feedback closes most loops. Prolactinoma, acromegaly, Cushing disease, Sheehan, central vs nephrogenic DI, and SIADH are the high-yield clinical packages.

Endocrine physiology on the CBSE is mechanism-first: how the signal arrives, which cell type secretes which product, how feedback should look when one level is fixed high or low, and which lesion breaks volume or osmolality control. Build a signaling map, then hang the hypothalamic–pituitary axes and the classic sellar lesions on it.

Hormone Classes and Receptor Logic

Hormones fall into three practical signaling families for exams.

Peptide and protein hormones (e.g., insulin, glucagon, GH, prolactin, ACTH, TSH, FSH, LH, PTH, ADH, oxytocin, hypothalamic releasing hormones) are hydrophilic. They cannot freely cross the plasma membrane, so they bind cell-surface receptors. Two major membrane classes dominate:

1. G protein–coupled receptors (GPCRs) — seven-transmembrane receptors coupled to heterotrimeric G proteins. Gs activates adenylyl cyclase → ↑cAMP → protein kinase A. Gi inhibits adenylyl cyclase. Gq activates phospholipase C → IP3 (Ca2+ release) and DAG (protein kinase C). Many anterior-pituitary–tropic receptors and catecholamine receptors use this pattern (e.g., ACTH via Gs-cAMP; TRH via Gq; ADH V1 via Gq, V2 via Gs).
2. Receptor tyrosine kinases (RTKs) and related kinase-linked receptors — ligand binding triggers dimerization and autophosphorylation (classic insulin and many growth-factor receptors) or JAK–STAT recruitment (GH and prolactin use cytokine-receptor–associated JAK2–STAT pathways rather than classical RTK catalytic domains). Downstream MAPK, PI3K–Akt, and transcriptional programs follow.

Steroid hormones (cortisol, aldosterone, estrogen, progesterone, testosterone, vitamin D as a steroid-like secosteroid) and thyroid hormones (T3/T4) are lipophilic. They cross membranes and bind intracellular nuclear receptors (type I cytosolic for many steroids with nuclear translocation; type II nuclear for thyroid hormone and others already DNA-associated). Ligand-bound receptors act as transcription factors at hormone response elements—slower genomic effects, though some non-genomic membrane actions exist at the margin of Step 1 emphasis.

Amino-acid–derived hormones split: catecholamines (tyrosine → dopamine, NE, epinephrine) behave like peptides at membrane GPCRs; thyroid hormones (tyrosine + iodine) behave like steroids at nuclear receptors; melatonin (tryptophan-derived) uses membrane receptors.

Storage pearl: Peptides are stored in secretory granules and released on stimulus. Steroids are synthesized on demand from cholesterol (limited preformed store). Thyroid hormone is stored as colloid thyroglobulin—an exception among "nuclear" hormones.

Hypothalamic Control of the Anterior Pituitary

Hypothalamic neurons release hypophysiotropic hormones into the hypophyseal portal system at the median eminence; these peptides reach anterior pituitary (adenohypophysis) cells at high local concentration.

Anterior pituitary cell types ("FLAT PiG" mnemonic variants):

• Corticotrophs → ACTH (POMC product; MSH and β-endorphin share the precursor)
• Thyrotrophs → TSH
• Gonadotrophs → FSH, LH
• Somatotrophs → GH
• Lactotrophs → prolactin

Acidophils traditionally stain GH and prolactin; basophils stain ACTH, TSH, FSH/LH—useful histology trivia when vignettes mention tinctorial class.

Pulsatility matters: Continuous GnRH suppresses gonadotrophs (basis of GnRH agonist "flare then down-regulation"); pulsatile GnRH supports fertility. Stress, illness, and hyperprolactinemia can suppress GnRH drive → hypogonadotropic hypogonadism.

Posterior Pituitary: ADH and Oxytocin

The posterior pituitary (neurohypophysis) does not synthesize its hormones. Magnocellular neurons in the supraoptic and paraventricular nuclei make ADH (vasopressin) and oxytocin, transport them down axons via the pituitary stalk, and release them into systemic capillaries.

• ADH: Primary stimuli are increased plasma osmolality (osmoreceptors) and substantial volume depletion/hypotension (baroreceptors). V2 receptors (renal collecting-duct principal cells, Gs-cAMP) insert AQP2 water channels → free-water reabsorption. V1 receptors (vascular smooth muscle, Gq) mediate vasoconstriction at high concentrations.
• Oxytocin: Milk ejection (myoepithelial contraction) and uterine contraction; positive feedback in labor is the classic exam story.

Stalk compression classically raises prolactin (loss of dopamine inhibition) while it can impair other anterior hormones and, if severe, ADH/oxytocin release.

Feedback Loops

Most axes use long-loop negative feedback: peripheral hormone inhibits hypothalamic and pituitary drive.

• Cortisol inhibits CRH and ACTH.
• Free T3/T4 inhibit TRH and TSH.
• IGF-1 and GH provide negative feedback on GHRH/GH; somatostatin provides inhibition.
• Sex steroids and inhibin modulate GnRH/FSH/LH (context-specific positive feedback of estrogen at midcycle is the ovulation exception).
• Prolactin is unusual: primary control is tonic dopaminergic inhibition from the hypothalamus; TRH can stimulate prolactin (hypothyroidism → hyperprolactinemia on exams).

Interpretation skill: High peripheral hormone + high tropic hormone suggests primary pituitary (or ectopic tropic) autonomy. High peripheral + suppressed tropic suggests peripheral autonomy or exogenous hormone. Low peripheral + high tropic suggests primary end-organ failure. Low peripheral + low/inappropriately normal tropic suggests central (hypothalamic/pituitary) failure.

Pituitary Adenomas and Mass Effects

Most adenomas are benign; clinical effects come from hormone excess and/or mass effect (headache, bitemporal hemianopia from optic chiasm compression, hypopituitarism of remaining axes).

Prolactinoma

Most common functioning adenoma. Hyperprolactinemia inhibits GnRH → low FSH/LH → hypogonadism (amenorrhea, infertility, decreased libido, osteoporosis risk). Galactorrhea may occur. Dopamine agonists (cabergoline, bromocriptine) shrink many prolactinomas and lower prolactin—first-line medical therapy is classic.

Acromegaly / Gigantism

GH-secreting somatotroph adenoma. Before epiphyseal closure → gigantism; after → acromegaly (enlarged hands/feet, coarsened facies, prognathism, organomegaly, insulin resistance/diabetes, cardiomyopathy, sleep apnea, colon polyps risk). Screen with IGF-1; confirm with failure of GH suppression on oral glucose tolerance testing in appropriate protocols. Somatostatin analogs, GH-receptor antagonist (pegvisomant), surgery, and radiation appear in treatment outlines.

Cushing Disease

Cushing disease = pituitary ACTH-secreting adenoma (to be distinguished from Cushing syndrome, the broader hypercortisolism phenotype). High ACTH → bilateral adrenal hyperplasia → high cortisol. High-dose dexamethasone often suppresses pituitary ACTH somewhat more than ectopic ACTH, though exams emphasize patterns over perfect numbers: pituitary Cushing often partially suppressible; ectopic ACTH (e.g., small cell lung cancer) often not; adrenal cortisol-producing tumor suppresses ACTH.

Nonfunctioning adenomas

Often present later with mass effect and hypopituitarism; may secrete inactive subunits. Stalk effect can raise prolactin modestly (usually lower than macroadenoma prolactinomas).

Sheehan Syndrome

Postpartum ischemic necrosis of the enlarged pregnant pituitary after severe obstetric hemorrhage/hypotension. Failure to lactate (prolactin loss), persistent amenorrhea, and progressive anterior hypopituitarism; posterior DI is less common than anterior failure but can occur. Acute adrenal crisis risk if ACTH is lost—stress-dose steroids conceptually matter.

Diabetes Insipidus vs SIADH

Central DI causes: idiopathic, trauma/surgery, tumors, infiltrative disease, autoimmune. Nephrogenic DI: lithium, hypercalcemia, hereditary V2/AQP2 defects. Water deprivation test logic: DI patients continue to put out dilute urine despite rising plasma osmolality; desmopressin distinguishes central (response) from nephrogenic (no response).

SIADH: euvolemic hypotonic hyponatremia, high urine osmolality and urine Na+ (natriuresis), low plasma uric acid often, normal thyroid/adrenal. Causes: CNS disease, lung disease (including small cell carcinoma ectopic ADH), drugs (SSRIs, carbamazepine), pain/nausea. Free water is retained; treatment concepts emphasize fluid restriction and addressing cause; demeclocycline/vaptans appear in advanced outlines.

Integration for CBSE Vignettes

When a stem shows amenorrhea + galactorrhea, think prolactin and dopamine tone. When hands/feet enlarge with diabetes and coarse features, think GH/IGF-1. When postpartum hemorrhage is followed by failure to lactate, think Sheehan. When polyuria with high plasma osmolality and low urine osmolality appears, decide DI vs primary polydipsia, then central vs nephrogenic. When euvolemic hyponatremia with concentrated urine appears after pneumonia or SSRI start, think SIADH—not volume depletion alone.

Master the receptor class, the portal anatomy, the feedback pattern, and the five classic clinical packages above, and most hypothalamic–pituitary CBSE items become pattern recognition rather than memorization noise.